Company data sheet · Keenova Therapeutics
Keenova Therapeutics: five lost years, and the economy wasn't the reason.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- Ireland
- Sources
- SEC filings (2013–2026), Stratrix's verified Decision Cases, market data and official economic statistics for Ireland
- Data as of
- November 1, 2026
- From profit to five straight losses. Keenova Therapeutics earned $3.1 billion in fiscal 2015–2017. Then it lost money every year from 2018 to 2023: $7.9 billion in all. 2024 was its first profit in six years: $0.5 billion.
- It wasn't the cycle. The losses began in 2018, a year Ireland economy grew 7.9% and factories added jobs. When a company falls while its economy grows, look inside the company first.
- Left behind by its peers. From 2016 to 2025, its revenue shrank 58% in US dollars; the median among 586 large manufacturers grew 58%. It outgrew only 1% of them.
- Leaders came and went. Keenova Therapeutics filed 38 leadership changes since 2016, more than 92% of large manufacturers (the median is 19).
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $3.4 billion | $0.6 billion | |
| 2017 | $3.2 billion | $2.1 billion |
As reported in its annual filings. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 95 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (0 with market data).
- Economic context: 6 measures for Ireland, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.